<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03214211</url>
  </required_header>
  <id_info>
    <org_study_id>YYPCT_APOLLO_OS</org_study_id>
    <nct_id>NCT03214211</nct_id>
  </id_info>
  <brief_title>Prospective Observational Study of Pravafenix Cap</brief_title>
  <official_title>Assess the Long-term Safety and Efficacy of Pravafenix Cap. in Korean Patients With Dyslipidemia: a Multicenter, Prospective, Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yooyoung Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yooyoung Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To observe the effiacay, safety and risk of developing diabetes, review the patients chars&#xD;
      who had administrated or neet to administrate the Pravafenix cap for enroll period, it is an&#xD;
      prospective observational study that only collect the collectable information follwoing the&#xD;
      hospital visiting date from enroll point to information collecting date. There is no extra&#xD;
      visit for this study.&#xD;
&#xD;
      Observe the data which has been collected for 3 yearts every year from enroll point, if the&#xD;
      patients agree to be participated in this study and are suitable in inclusion/exclusion&#xD;
      criteria.&#xD;
&#xD;
      If the lipid-lowering drugs(only Ezetimibe is possible) is add-on the Pravafenix Cap&#xD;
      administrating period, it will be analyzed by laering analysis separately. But, the reason&#xD;
      why it is add-on to have to be written on e-CRF.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 30, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence and mortaity about the cardiovascular disease case for 3 years from administrating the Pravafenix Cap.</measure>
    <time_frame>For 3 years</time_frame>
    <description>(Occurence of the MACE for 3 years after aministrating the Pravfenix Cap)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Variation of the diabetic index (Before/after the administration of the Pravafenix Cap)</measure>
    <time_frame>For 3 years</time_frame>
    <description>FBS, HbA1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation of lipid parameter(Before/after the administration of the Pravafenix Cap)</measure>
    <time_frame>For 3 years</time_frame>
    <description>TC, LDL-C, TG, HDL-C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation of inflammatory index(Before/after the administration of the Pravafenix Cap)</measure>
    <time_frame>For 3 years</time_frame>
    <description>hs-CRP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of the major clinical events</measure>
    <time_frame>For 3 years</time_frame>
    <description>eventsBefore/after the administration of the Pravafenix Cap.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">3088</enrollment>
  <condition>Dyslipidemias</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who have dyslipidemia, already administrated or need to administrate the&#xD;
        Pravafenix Cap.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Among the patients with artheriosclerotic cardiovascular heart failure who have been&#xD;
        hopitalized or visited the hospital.&#xD;
&#xD;
          1. Men or Women over 20 years old&#xD;
&#xD;
          2. Patients who had already administrated or need to administrate the Pravafenix Cap&#xD;
&#xD;
          3. Patients who have abnormal opinion(dyslipidemia) about LDL-C, TG, HDL-C at the enroll&#xD;
             point&#xD;
&#xD;
               -  70mg/dL ≤ LDL-C ≤ 160mg/dL&#xD;
&#xD;
               -  150mg/dL ≤ TG ≤ 500mg/dL or HDL-C &lt; 40mg/dL(Men), 50mg/dL(Women)&#xD;
&#xD;
          4. Voluntary written informed consent to study participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient who have hypersensitivity about Pravafenix Cap or ingredients of the&#xD;
             Pravafenix Cap.&#xD;
&#xD;
          2. Patients suffer from liver disease (Biliary cirrhosis, activated hepatophay or lasting&#xD;
             potentiation of the transaminase 3 times excess from normal valus(which has no cause).&#xD;
&#xD;
          3. Patients suffer from kidney disease(CCR &lt; 60ml/min)&#xD;
&#xD;
          4. Patients have photo-allergy (allergic reaction causeed by sunlight or exposure to UV&#xD;
             light) or phototoxic reactions (damage to skin caused by exposure to sunlight or UV&#xD;
             light) during treatment with fibrates(lipid-modifying medicines) or ketoprofen (an&#xD;
             anti-inflammatory medicine that can be used orally or on the skin for muscle and bone&#xD;
             disorders, and orally for gout or period pain).&#xD;
&#xD;
          5. Acute or chronic patients who have high triglycerides academia.&#xD;
&#xD;
          6. Pregnant or breat-feeding&#xD;
&#xD;
          7. Someone who have a history of muscle problems during treatment with&#xD;
             cholesterol-controlling medicines called 'statins' (such as simvastatin, atorvastatin,&#xD;
             pravastatin or rosuvastatin) or fibrates (such as fenofibrate and bezafibrate).&#xD;
&#xD;
          8. Pateints who have uncontrolled hypothyroidism or hyperthyroidism.&#xD;
&#xD;
          9. Patinets who couldn't be participated in the study by the other opinion of the&#xD;
             investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Myung-Ho Jeong, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonnam National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Min-Kyung Kwon, Manager</last_name>
    <phone>82-2-6202-7104</phone>
    <email>mkkwon@yypharm.co.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Seul-Gi Ha, Ass. Manager</last_name>
    <phone>82-2-6202-7105</phone>
    <email>sgha@yypharm.co.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chonnam national university hospital</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <contact>
      <last_name>Myung-Ho Jeong, Ph.D</last_name>
      <email>myungho@chollian.net</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>June 21, 2017</study_first_submitted>
  <study_first_submitted_qc>July 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2017</study_first_posted>
  <last_update_submitted>August 30, 2017</last_update_submitted>
  <last_update_submitted_qc>August 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

